Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Not listed Not applicable Interventional

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

NCT01599884
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
N-acetylcysteine, Oral acetylcysteine
Drug
Lead sponsor
Center for Veterans Research and Education
Other
Eligibility
40 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional

The Effect of OMT on Patients With COPD: Correlating Pulmonary Function Tests With Biochemical Alterations

NCT01582958
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Osteopathic Manipulative Treatment (OMT), sham omt
Procedure · Other
Lead sponsor
Michigan State University
Other
Eligibility
49 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK Study of PT003 and PT001 in Japanese Healthy Subjects

NCT02196714
View directory record Official record
Conditions
COPD
Interventions
Glycopyrronium and Formoterol Fumarate (GFF) Dose 1, Glycopyrronium and Formoterol Fumarate (GFF) Dose 2, Glycopyrronium (GP) Dose 1, Glycopyrronium (GP) Dose 2
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 25, 2026, 4:14 AM EDT
Completed No phase listed Observational

Pulmonary Function Changes in 10 Pack Year Smokers With Chronic Bronchitis

NCT00454675
View directory record Official record
Conditions
Chronic Bronchitis, COPD
Interventions
Not listed
Lead sponsor
Westside Family Medical Center, P.C.
Other
Eligibility
40 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 15, 2008 · Synced Oct 25, 2026, 4:14 AM EDT
Completed No phase listed Observational

Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease

NCT00725309
View directory record Official record
Conditions
Emphysema, Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

NCT04751487
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
59
States / cities
Phoenix, Arizona • Fresno, California • Palm Springs, California + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD

NCT03094806
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Acapella Vibratory PEP Therapy Device plus usual care, Sham Acapella Vibratory PEP Device plus usual care
Device
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Study in Patients With COPD

NCT00215384
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
50 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
7
States / cities
Los Angeles, California • Upland, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Not applicable Interventional Results available

Venovenous CO2 Removal (VVCO2R) in Patients With COPD and Acute Respiratory Failure

NCT00594009
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Venovenous CO2 Removal (VVCO2R) in COPD
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 4 Interventional

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

NCT03611699
View directory record Official record
Conditions
COPD
Interventions
Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo
Drug
Lead sponsor
Gary L. Pierce
Other
Eligibility
30 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing

NCT02514798
View directory record Official record
Conditions
COPD
Interventions
Esophageal and gastric balloons, Respiratory Inductance Plethysmography (RIP) system, Sentec transcutaneous monitoring system, High-flow humidified nasal oxygen delivery system, CPAP (Positive Control)
Other · Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust

NCT03089515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lower Respiratory Disease
Interventions
Cardio-Pulmonary Exercise Testing (CPET)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 25, 2026, 4:14 AM EDT
Completed No phase listed Observational Results available

Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)

NCT00549445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated No phase listed Observational

A Study of Patients With Chronic Disease

NCT04263727
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Colorado Springs, Colorado • Clearwater, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)

NCT06524856
View directory record Official record
Conditions
Dyspnea, Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Lung Master (Pulmonary Exerciser)
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD

NCT00648245
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
BIO-11006 Inhalation Solution, Placebo, BIO-11006
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
45 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Glendale, Arizona • Los Angeles, California • Bay Pines, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

NCT01005901
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
33
States / cities
Birmingham, Alabama • Fairhope, Alabama • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694
View directory record Official record
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01089127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
69
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

NCT06075095
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
19
States / cities
Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

NCT00103922
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
cilomilast
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
115
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 25, 2026, 4:14 AM EDT
Withdrawn No phase listed Observational

Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD

NCT05661435
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
RESP Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT03034967
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Danirixin matching placebo, Standard of care, Rescue medication
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Birmingham, Alabama • Topeka, Kansas • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 25, 2026, 4:14 AM EDT